While some racial and ethnic groups have been underrepresented in clinical trials of therapies for lung cancer, breast cancer and other malignancies, researchers speculated that the situation might be different for adult leukemia trials. The unique features of the disease — the speed with which it needs to be treated after diagnosis, the delivery of … Read more
Even as science has removed all doubt about the link between environmental factors like tobacco smoke and lung cancer, the role of genetics in people’s risk of the disease has been much harder to pin down. A study by Dana-Farber investigators provides new evidence that, in people with lung cancer, genetic ancestry can influence the … Read more
In an era when targeted therapies are often effective against multiple types of cancer, the U.S. Food and Drug Administration’s accelerated approval of a two-drug therapy for solid tumors carrying a specific mutation in the BRAF gene is a prime example of this trend. For patients with glioma brain cancer that harbors the mutation, the … Read more
Scientists are stepping up efforts to deploy natural killer (NK) cells — the body’s first responders against infected and malignant cells — to combat cancer. Treatment using NK cells from healthy donors has shown promise, but currently successes have been limited and the cells lack staying power in the body. While some researchers are working … Read more
CAR T cells’ superpower is to identify cancer-related targets on the surface of tumor cells and order an attack on those cells. But they lack anything resembling X-ray vision to detect nefarious protein targets within tumor cells. That shortfall has limited their effectiveness in diseases like acute myelogenous leukemia (AML), in which tumor cells display few surface … Read more
For many years, the human genome was viewed as a book of life in which sections of great eloquence and economy of expression were interspersed with vast stretches of gibberish. The legible sections contained the code for making cell proteins; the other regions, representing about 90% of the entire genome, were dismissed as “junk DNA,” … Read more
Results of several phase 3 trials and dozens of other studies led by Dana-Farber researchers were presented online and in person June 3-7 at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), the world’s largest clinical cancer research meeting. Some of the research reports presented by Dana-Farber investigators include: Improved progression-free … Read more
The cells in our body replicate themselves in a tightly regulated series of steps and molecular checkpoints that act as gatekeepers. A set of proteins called cell cycle kinases, including CDK1, CDK4, and CDK6, control various phases and timing of the process so that cells divide and replicate only when needed, and under strict control. … Read more
When a dam collapses because of a design flaw, tracing the error to the original blueprint is a relatively straightforward matter. When the breach happens for another reason — shoddy workmanship, insufficient oversight during construction, a failure to follow design specifications, or any of a range of other possibilities — the investigation can be much … Read more
When lab tests confirmed that her non-Hodgkin lymphoma (NHL) had recurred after treatment, Ann Bonetti came to Dana-Farber expecting to hear she would need a stem cell transplant. When her oncologist told her about a clinical trial of a treatment that would turn her body’s own T cells into ace cancer fighters, she didn’t need … Read more
Stephan Bunker has learned to be prepared for anything during a half-century protecting others as a soldier, volunteer firefighter, law enforcement official, and director of 911 dispatchers for the state of Maine. So when Bunker was the one facing an emergency — a diagnosis of a brain cancer known as primary central nervous system (CNS) … Read more
This post was adapted from a Broad Institute post by Allessandra DiCorato. Over the last two decades, researchers have discovered thousands of genetic mutations in cancer. But understanding how they affect the growth and spread of tumors in the body remains challenging because each patient’s tumor can have many different mutations. Now, scientists have used … Read more
Treating advanced prostate cancer typically involves surgery — to reduce levels of testosterone, which fuels the growth of tumors — or giving drugs that blockade the androgen receptor (AR), which responds to testosterone by stimulating cancer-growth genes. While these measures can keep the disease at bay initially, resistance almost always occurs as the androgen receptor … Read more
At 28 years old, Dana-Farber bioinformatics analyst Carino Gurjao is already making a splash in the field of colorectal cancer research. He is coming off the back of a big year: The Paris-born researcher was named to Forbes Healthcare’s 2022 30 Under 30 list for his role in the Giannakis Lab at Dana-Farber, which identified … Read more
Approximately one in three children in the United States lives in a low-income home. For childhood cancer patients, living in a low-income home can have a significant impact: Poverty and associated factors are linked to poorer outcomes, even at large academic medical centers like Dana-Farber, according to research by Kira Bona, MD, MPH, a pediatric … Read more
People with disabilities that affect their mobility often face special challenges when diagnosed with cancer. Beyond logistical matters such as getting to and from medical appointments, they may be diagnosed with more advanced, harder-to-treat cancer than non-disabled individuals, making them more likely to die of their disease, research suggests. While most previous studies of these … Read more
Investigators had culled the list of suspects down to two. But which one was the guilty party, or were both? The pair worked together so seamlessly, it was difficult to tell where one’s role began and the other’s ended. In some respects, they even looked alike. Dana-Farber scientists have now teased apart the relationship between … Read more
A rare leukemia called BPDCN (blastic plasmacytoid dendritic cell neoplasm) is three to four times more common in people with one X chromosome, for reasons that hadn’t been clear. Now, however, research led by Dana-Farber Cancer Institute scientists has identified a genetic factor that appears to explain a large part of the discrepancy, and also … Read more
Born on Jan. 1, Alan Morris is used to sharing a birthday with the New Year. Now the lymphoma patient also has a special day marking what he considers his rebirth — and a harbinger of hope. On Jan. 24, Morris, 58, became the first Dana-Farber Brigham Cancer Center patient to receive outpatient CAR T-cell … Read more
At Carolyn Kershaw and Darlene Musso’s first visit to Dana-Farber in July, Irene Ghobrial, MD, greeted them with some unexpected news. “We walked in and she said, ‘Did you know you two are famous in our lab?’” Kershaw recounts. Their local renown stems from their participation in the PROMISE study at Dana-Farber’s Center for the Prevention of Progression (CPOP), which … Read more